Bloody Minded

One molecule to rule them all, one molecule to find them. One molecule to bring them all, and in the liver bind them. Hepcidin is the key to understanding iron metabolism and we examine how iron gets into, around and out of the body. We promise not to be too Celebrimbor-ing as you join Nick, Cale and Bashar  for this discussion of the basic science of iron handling in preparation for our journey into the building blocks of blood. Welcome to Lord of the Haematinics. 
TIMESTAMPS

0:56 - The next arc of the Bloody Minded Cinematic Universe
3:23 - Series overview
6:21 - Basic iron metabolism
7:54 - The three main player groups in iron metabolism
8:44 - Iron binding molecules: Heme
13:22 - Non-heme iron
14:05 - Iron binding molecules: Ferritin
17:12 - Iron binding molecules: Transferrin
20:44 - Iron transporters: DMT1
25:02 - Iron transporters: ferroportin
28:21 - Iron transporters: Hephaestin
29:28 - Iron flux
33:24 - Hepcidin: Master Regulator and The One Ring
39:04 - Non-hepcidin regulation of Ferroportin and IREs
41:32 - Take home messages
Support the show
Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au

Has your ward team been hit with HITT? Is Jane the only Fonda you know? Is BAD an 80s hit and not a trio of anti-coagulation infusions (Bivalirudin, Argatroban and Danaparoid). Is Alison showing her age? Never fear; join Alison, Bashar, Nick and Cale as they aim to de-mystify less commonly used anticoagulation that may come up on the wards. 
TIMESTAMPS
0:56 - It's Fancypants Wednesday!
2:15 - Episode overview
4:37 - Fondaparinux
9:07 - When to use fonda
12:35 - Argatroban
17:25 - When to use argatroban
18:02 - Bivalirudin
19:11 - Mandatory historical diversion
22:50 - Back to bivali business
25:59 - Danaparoid
30:21 - When to use danaparoid
32:45 - Quick summary
34:13 - Dalteparin
38:02 - A bit of nonsense chitchat
Support the show
Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au

Join us in our third straight week of incredibly nice and incredibly talented haematology gurus as Professor John Moore joins us as an expert guest to discuss stem cell transplant in the myeloid disease setting. 
TIMESTAMPS
 1:00 – HYTTIOAOA
 1:47 – Introducing Professor John Moore
 8:06 – Advice to RMOs on the Allo Term
 11:02 – The history of allogeneic transplantation
 18:26 – Modern morbidity/mortality from alloSCT for AML
 23:05 – Use of transplant scoring systems
 27:29 – The role of MRD in transplant decisions
 30:04 – MAC vs. RIC – Choice of Conditioning
 38:15 – The role of PTCy
 40:17 – Second allogeneic transplants
 42:02 – DLI
 43:08 – Biallelic TP53 – no good options
 45:29 – Free rein in the trials space
 49:11 – AlloSCT/CAR-T for autoimmune disease
 55:05 – Take Home Messages 
Support the show
Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au

This week we continue the pattern of guests who are really really ridiculously good at haematology and also really really ridiculously nice people as well. We are very excited to be joined by Dr Michael Krigstein who many of you would know as the a molecular haematology guru who has gotten countless patients through their diagnoses and countless haematology trainees through their exams.
Timestamps:
01:30 - Introducing Dr Michael Krigstein
04:23 - Getting into Lab Haem
08:30 - The Mechanics of NGS
16:57 - Learning to report - RCPA Modules
19:58 - After the NGS - Curation
24:14 - NGS - Not a panacea
28:45 - Why NGS is bad at ITDs
32:42 - Panel Design
36:37 - RNA vs DNA Panels
39:16 - The future of NGS in haematology
46:56 - A standout case
53:36 - Wrapup

Support the show
Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au

What happens when you take someone who is really really ridiculously good at haematology and also a really really ridiculously nice person as well? You get Dr Jad Othman, consultant Haematologist and Haematopathologist at Royal North Shore Hospital in Sydney who will be joining us today to discuss the use of measurable residual disease in acute myeloid leukaemia.
Dr Othman is well suited to this topic, having written his doctoral thesis on molecular disease assessment in AML, sitting on the European LeukaemiaNet (ELN)-DAVID MRD Working Group as well as numerous ALLG AML and MDS working groups. We're delighted to have him field the Bloody Minded Crew's questions today. 
Timestamps
01:00 - The boys making outdated millenial references
02:50 - Getting to know Dr Jad Othman
09:50 - The concept of MRD
11:55 - Lab techniques for MRD
17:59 - Why doesn't everyone have an MRD marker?
20:51 - What makes a good MRD assay?
24:14 - Patients without a molecular MRD marker
26:21 - Clinical case
30:30 - What we do with MRD results
31:47 - The NPM1/FLT3 PB/BM situation
35:31 - Why MRD is actually helpful
39:40 - Why single agent treatment in AML is challenging
44:33 - The 2025 ELN DAVID update
48:44 - Does doing MRD improve OS?
52:21 - The INTERCEPT study
55:41 - Wrap up and summary

Support the show
Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au